Drug Profile
Research programme: psoriasis therapeutics - Nxera Pharma
Alternative Names: SD 208Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Sosei
- Developer Nxera Pharma
- Class
- Mechanism of Action Cytokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Psoriasis